Latest Biotech Startup Funding Rounds
Financing for drug discovery, therapeutics and biological technologies, with the development context behind each round.
- Rounds
- 473 All time
- Disclosed funding
- $19.6B 400 disclosed amounts
- Median round
- $20M Of disclosed amounts
| Company | Amount | Round | Sector | Country | Investors | Announced |
|---|---|---|---|---|---|---|
| AG Alithea GenomicsCompany profile Alithea Genomics supplies RNA-sequencing preparation kits and services for laboratories running large gene-expression and drug-screening studies. Alithea Genomics supplies RNA-sequencing preparation kits and services for laboratories running large gene-expression and drug-screening studies. | CHF 3M | Seed | Biotech | Switzerland | Investors | |
| S ShellworksCompany profile Develops bio-based plastic alternative materials for packaging and consumer goods Develops bio-based plastic alternative materials for packaging and consumer goods | $15M | Series A | Biotech, Climate tech | United Kingdom | Investors | |
| M MycoverseCompany profile Developing fungal-based biological crop protection solutions using AI-driven discovery platform Developing fungal-based biological crop protection solutions using AI-driven discovery platform | €2.4M | Pre-SeedPre-seed | Biotech, Agritech | Denmark | Investors | |
| PT Poplar TherapeuticsCompany profile Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions Developing a new class of anti-IgE therapy to treat food allergy and other atopic conditions | $45M | Series A+Series A | Biotech | United States | Investors | |
| A ALORACompany profile Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. Agricultural biotechnology company developing gene-edited crop traits to improve yield under heat and salinity stress. | Undisclosed | Undisclosed | Biotech, Agritech | United Kingdom | Investors | |
| b Develops an AI-powered bioproduction platform for industrial ingredients | €7M | Seed | Biotech | France | Investors | |
| A AntiverseCompany profile Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. Antiverse designs therapeutic antibodies for difficult drug targets using generative AI, engineered cell lines and in-house laboratory testing. | $9.3M | Series A | Biotech, Healthtech | United Kingdom | Investors | |
| B Develops AI platform for targeted crop protection solutions | $3.8M | Seed | Biotech, Agritech | United Kingdom | Investors | |
| OB Develops AI-driven models to decode human microbiology | $3.5M | Pre-SeedPre-seed | Biotech | United Kingdom | Investors | |
| B BreezeBioCompany profile Develops genetic medicines enabled by precise, non-viral nanoparticle delivery across tissues Develops genetic medicines enabled by precise, non-viral nanoparticle delivery across tissues | $60M | Series B | Biotech | United States | Investors |
Active investors in this selection
All investors →Ranked by rounds participated in · All time
- 1RA Capital Management
Estuary Biotherapeutics, Circle Pharma, Inc., Solstice Oncology
22rounds3led - 2Janus Henderson Investors
Star Therapeutics, OMass Therapeutics, Soufflé Therapeutics
15rounds1led - 3Eli Lilly and Company
BigHat Biosciences, Circle Pharma, Inc., Moonwalk Biosciences
15rounds0led - 4ARCH Venture Partners
Soufflé Therapeutics, Encoded Therapeutics Inc., Moonwalk Biosciences
14rounds0led - 5OrbiMed
Star Therapeutics, Leal Therapeutics, Accro Bioscience
11rounds1led
Latest digests
Archive →Explore published rounds while the next edition is being prepared.